Developmental effects of propyphenazone in analgesic and antipyretic combination with caffeine or paracetamol

Human and Experimental Toxicology

Volumn 23, Issue 5, 2004, Pages 235-244

  Burdan, Franciszek ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Acetaminophen; Caffeine; COX 1; COX 2; Cycloxygenase inhibitor; Intrauterine growth retardation; Isopropylantipyrine; Pregnancy; Prenatal toxicity

Indexed keywords

CAFFEINE; NON PRESCRIPTION DRUG; PARACETAMOL; POLYSORBATE 80; PROPYPHENAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY HEIGHT; CALCULATION; CONGENITAL MALFORMATION; CONTROLLED STUDY; DIGESTIVE SYSTEM MALFORMATION; DOSE RESPONSE; DRUG FORMULATION; ENVIRONMENTAL EXPOSURE; FEMALE; FETUS; FETUS DEATH; FETUS WEIGHT; GASTROSCHISIS; GESTATIONAL AGE; HYSTERECTOMY; INTRAUTERINE GROWTH RETARDATION; LOW DRUG DOSE; MORTALITY; NIDATION; NONHUMAN; OPTIMAL DRUG DOSE; PLACENTA WEIGHT; PREGNANCY; PRENATAL DEVELOPMENT; PRIORITY JOURNAL; RAT; RAT STRAIN; SKELETON MALFORMATION; UMBILICAL HERNIA;

ACETAMINOPHEN; ADMINISTRATION, ORAL; ANALGESICS, NON-NARCOTIC; ANIMALS; ANTIPYRINE; CAFFEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EMBRYONIC DEVELOPMENT; FEMALE; FETAL DEVELOPMENT; FETAL WEIGHT; ORGAN SIZE; PLACENTA; PREGNANCY; RATS; RATS, WISTAR; TOXICITY TESTS;

RATTUS NORVEGICUS;

EID: 3042683752     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327104ht439oa     Document Type: Article

References (70)

1. ASHP Commission on Therapeutics. ASHP therapeutic position statement on the safe use of oral nonprescription analgesics. Am J Health Syst Pharm 1999; 56: 1126-31.
2. Barkin RL. Acetaminophen, aspirin, or ibuprofen in combination analgesic products. Am J Ther 2001; 8: 433-42.
3. Tassinari MS, Cook JC, Hurtt ME. NSAIDs and developmental toxicity. Birth Defects Res (Part B) 2003; 68: 3-4.
4. Cook JC, et al. Analysis of the nonsteroidal anti-inflammatory drug literature for potential developmental toxicity in rats and rabbits. Birth Defects Res (Part B) 2003; 68: 5-26.
5. McMurray RW, Hardy KJ. COX-2 inhibitors: today and tomorrow. Am J Med Sci 2002; 323: 181-89.
6. Dannhardt G, Kiefer W. Cyclooxygenase inhibitors - current status and future prospects. Eur J Med Chem 2001; 36: 109-26.
7. Chan TYK. Improvements in the packaging of drugs and chemicals may reduce the likelihood of severe intentional poisonings in adults. Hum Exp Toxicol 2000; 19: 387-91.
8. Li DK, Lu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage. BMJ 2003; 327: 368-71.
9. Kunovits G. Product monograph propyphenazone (Isopropylantipyrine). In: Kunovits G. Saridon Tablests, Ro 11-6655/002 Summary product characteristic. Basel: Hoffman-La Roche Press, 1996.
10. United Nations. Consolidated list of products whose consumption and/or sale have been banned, withdrawn, severely restricted or not approved by governments (ST/ESA/239-E.94IV.3). New York, NY: United Nations Publication, 1994: 138-139, 545-546.
11. Okonek S. Intoxication with pyrazolones. Br J Clin Pharm 1980; 10: 385S-90S.
12. The International Agranulocytosis and Aplastic Anemia Study. Risk of agranulacytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. JAMA 1986; 256: 1749-57.
13. Manfred V, Kellner HM. Kinetic and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone). Br J Clin Pharm 1980; 10: 299S-308S.
14. Schwab JM, Schluesener HJ, Laufer S. COX-3: just another COX or the solitary elusive target of paracetamol? Lancet 2003; 361: 981-82.
15. Kiersch TA, Minic MR. The onset of action and the analgesic efficacy of Saridon (a propyphenazone/paracetamol/caffeine combination) in comparison with paracetamol, ibuprofen, aspirin and placebo (pooled statistical analysis). Curr Med Res Opin 2002; 18: 18-25.
16. Nehlig A, Debry G. Potential teratogenic and neurodevelopmental consequence of coffee and caffeine exposure: a review on human and animal data. Neurotoxicol Teratol 1994; 16: 531-43.
17. Christian MS, Brent RL. Teratogen update: evaluation of the reproductive and developmental risk of caffeine. Teratology 2001; 64: 51-78.
18. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk, fifth edition. Baltimore, MD: Williams & Wilkins, 1998: 4-8, 125-31.
19. Colomina MT, Albina ML, Sanchez DJ, Domingo JL. Interactions in developmental Toxicology: combined action of restraint stress, caffeine, and aspirin in pregnant mice. Teratology 2001, 63: 144-51.
20. Prescott LF. Effects on pregnancy and the newborn. In Paracetamol (acetaminophen): a critical bibliographic review. London: Taylor & Francis, 1996: 393-94.
21. Burdan F. [Prenatal toxicity of paracetamol]. Pol Merkuriusz Lek 1999; 7: 289-91, in Polish.
22. Kraetsch HG, et al. Analgesic effect of propyphenazone in comparison to its combination with caffeine. Eur J Clin Pharmacol 1996; 49: 377-82.
23. Burdan F, Wyskiel M. Embryotoxic effect of low doses of caffeine. Ann Univ Mariae Curie Sklodowska [Med] 1999; 54: 67-73.
24. Burdan F, et al. The effects of short-time caffeine administration on skeleton development in Wistar rats. Folia Morphol (Warsz) 2000; 59: 91-95.
25. Burdan F. Evaluation of bone formation in fetal skeletons following prenatal paracetamol administration in single-stained specimens in Wistar rats. Folia Morphol (Warsz) 2000; 59: 167-71.
26. Burdan F. Somatic and skeleton development of rat foetuses following in-utero exposure to isopropylantipyrine (propyphenazone) during the second trimester of gestation. Folia Morphol (Warsz) 2000; 59: 317-22.
27. Burdan F, Siezieniewska Z, Kis G, Blicharski T. Embryofetotoxicity of acetaminophen in in-vivo experimental model. Ann Univ Mariae Curie Sklodowska [Med] 2001; 56: 89-95.
28. Burdan F. Formation of the knee joint after prenatal propyphenazone (isopropylantipyrine) administration. Cells Tissues Organs 2002; 171: 145-51.
29. Christian MS. Test methods for assessing female reproductive and developmental toxicology. In Hayes AW ed. Principles and methods of toxicology, fourth edition. Philadelphia, PA: Taylor & Francis, 2001: 1301-81.
30. http://www.DevTox.org/nomenclature/organ.htm
31. Burdan F. Effects of prenatal exposure to combination of acetaminophen, isopropylantipyrine and caffeine on intrauterine development in rats. Hum Exp Toxicol 2002; 21: 25-31.
32. Burdan F. Intrauterine growth retardation and lack of teratogenic effects of prenatal exposure to the combination of paracetamol and caffeine in Wistar rats. Reprod Toxicol 2003; 17: 51-58.
33. Burdan F, Siezieniewska Z, Urbanowicz Z. Combined effects of acetaminophen, isopropylantipyrine and caffeine on pregnant and nonpregnant liver. Hum Exp Toxicol 2001; 20: 469-575.
34. Hasegawa Y et al. Studies on 5-aminoalkyl- and 3-aminoalkylisoxazoles and related derivatives. Part XIII. Teratology studies on 3-(1-hydroxy-2-pipridinoethyl)-5-phenylisoxazole in rats and mice. Annu Rep Shionogi Res Lab 1972; 22: 109-20.
35. Tanabe K. Hypersensitive toxicity of 5-n-butyl-1-cyclohexyl-2,4,6-trioxoperphydropyrimidine in the pregnant rat. Jpn J Pharmacol 1967; 17: 381-92.
36. Takeno S, Sumita M, Saito H, Sakai T. Strain differences in susceptibility to the embryotoxic effects of aminipyrine in mice. Res Commun Chem Pathol Pharmacol 1987; 57: 409-19.
37. Adrian RW, Walker FS, Noel PRB. Toxicological studies on azapropazone. Curr Med Res Opin 1976; 4: 17-34.
38. Gaetani M, Debeus R. Toxicological investigations of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) 2. Study of teratogenic activity in rabbits and rats. Arzneimittelforschung 1972; 22: 223-26.
39. Yegnanaryan R, Jogleker GV. Anti-fertility effect of non-steroidal anti-inflammatory drugs. Jpn J Pharmacol 1978; 28: 909-17.
40. Schardein JL, Blatz AT, Woosley ET, Kaump DH. Reproduction studies on sodium meclofenamete in comparison to aspirin and phenylbutazone. Toxicol Appl Pharmacol 1969; 15: 46-55.
41. Lubawy WC, Burriss-Garret RJ. Effect of aspirin and acetaminophen on fetal and placental growth in rats. J Pharm Sci 1977; 66: 111-13.
42. Wyskiel M. Influence of acetylsalicylic acid and paracetamol on embryonal and fetal development in Wistar rat. - Ph.D. Thesis. Lublin: Medical University of Lublin, 1998.
43. Reel J, Lawton AD, Lamb JC. Reproductive toxicity evaluation of acetaminophen in Swiss CD-1 mice using a continuous breeding protocol. Fundam Appl Toxicol 1992; 18: 233-39.
44. Patel P. Toxicity of over-the-counter stimulants. J Am Med Assoc 1984; 252: 1898-903.
45. Aeschbacher HU, Milon H, Poot A, Wurzner HP. Effect of caffeine on rat offspring from treated dams. Toxicol Lett 1980; 7: 71-77.
46. Collins TFX, et al. Potential reversibility of skeletal effects in rats exposed in utero to caffeine. Food Chem Toxicol 1987; 25: 647-62.
47. Elamzar MMA, McElhatton PR, Sullivan FM. Studies on the teratogenic effects of different oral preparations of caffeine in mice. Toxicology 1982; 23: 57-71.
48. Skalko RG, Poche PD, Kwasigroch TE. The toxicology of chemical interactions during pregnancy in the mouse: caffeine and phenytoin. Toxicology 1984; 30: 7-16.
49. Scott WJ Jr. Caffeine-induced limb malformations: description of malformations and quantitation of placental transfer. Teratology 1983; 28: 427-35.
50. Mutter TF. Caffeine and reduction of fetal ossification in the rat: fact or artifact? Teratology 1988; 37: 239-47.
51. Nishimura H, Nakai K. Congenital malformation in offspring of mice treated with caffeine. Proc Soc Exp Biol Med 1960; 104: 140-42.
52. Beck SL, Urbano CM. Acetazolamide with caffeine causes exencephaly in "resistant" SWV mice. Reprod Toxicol 1993; 7: 123-29.
53. Beck SL, Urbano CM. Potentiating effect of caffeine on teratogenicity of acetazolamide in C57BL/6J mice. Teratology 1991; 44: 241-50.
54. Fujii T, Nakatsuka T. Potentiating effects of caffeine on teratogenicity of alkylating agents in mice. Teratology 1983; 28: 29-33.
55. Vogel R, Spielmann H. Potentiating effect of caffeine on embryotoxicity of cyclophosphamide treatment in vivo during the preimplantation period. Teratog Carcinog Mutagen 1987; 7: 169-74.
56. Ritter EJ, Scott WJ Jr, Randall JL, Ritter JM. Teratogenicity of di(2-ethylhexyl)phthalate, 2-ethylhexanol, 2-ethylhexanoic acid and valproic acid and potentiation by caffeine. Teratology 1987; 35: 41-46.
57. Clark RL, Eschbach K, Cusick WA, Heyse JF. Interactions between caffeine and adenosine antagonists in producing embryo resorptions and malformations in mice. Toxicol Appl Pharmacol 1987; 91: 371-85.
58. Fadel RAR, Persaud TVN. Effects of alcohol and caffeine on cultured whole rat embryos. Acta Anat 1992; 144: 114-19.
59. Nash JE, Persaud TVN. Influence of nicotine and caffeine on rat embryonic development. Histol Histopathol 1998; 3: 377-88.
60. Martinez-Feias ML, Rodriguez-Pinilia E, Prieto L. Prenatal exposure to salicylates and gastroschisis: a case-control study. Teratology 1997; 56: 241-43.
61. Torfs CP, et al. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 1996; 54: 84-92.
62. Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. Teratology 1992; 45: 361-67.
63. Hoyme HE, Higginbottom MC, Jones KL. The vascular pathogenesis of gastroschisis: intrauterine interruption of the omophalomesenteric artery. J Pediatr 1981; 98: 228-31.
64. Streck RD, Kumpf SW, Ozolins TRS, Stedman DB. Rat embryos express transcripts for cyclooxygenase-1 and carbonic anhydrase-4, but not for cyclooxygenase-2, during organogenesis. Birth Defects Res (Part B) 2003; 68: 57-69.
65. Stanfield KM, et al. Expression of cyclooxygenase-2 in embryonic and fetal tissues during organogenesis and late pregnancy. Birth Defects Res (Part A) 2003; 67: 54-68.
66. Burdan F, et al. Prenatal effects of DuP-697 - the irreversible, highly selective cyclooxygenase-2 inhibitor. Reprod Toxicol 2003; 17: 413-19.
67. Cappon GD, Cook JC, Hurtt ME. Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure. Birth Defects Res (Part B) 2003; 68: 47-56.
68. Chahoud I, Ligensa A, Dietzel L, Faqi AS. Correlation between maternal toxicity and embryo/fetal effects. Reprod Toxicol 1999; 13: 375-81.
69. Koren G. Maternal-fetal toxicology. A clinician's guide, second edition. New York, NY: Marcel Dekker, 1994.
70. McElhatton PR, Sullivan FM, Volans GN, Fitzpatric R. Paracetamol poisoning in pregnancy: an analysis of the outcomes of cases referred to the Teratology Informative Service of the National Poisons Information Service. Hum Exp Toxicol 1990; 9: 147-53.